Summary of this article
Indian pharmaceutical stocks came under broad selling pressure on Wednesday after US President Donald Trump unveiled a phased tariff roadmap for imported generic medicines, sparking concerns over the long-term outlook for Indian drugmakers that rely heavily on the world's largest pharmaceutical market.
